Fundraise

China's Xihe Superconducting raises Series C in fusion magnet bet

What's the deal? Xihe Superconducting TechnologyDealroom has a profile for this one. Try Dealroom →, a Hefei-based maker of superconducting and cryogenic equipment, has closed a Series C round led by Guoxin FundDealroom has a profile for this one. Try Dealroom → and Guoshou Equity. Guoke Capital, Greater Bay Area Homeland Investment, Jianxin Equity, China Merchants China Fund, Beigong Investment, TCL CapitalDealroom has a profile for this one. Try Dealroom →, Tiantu CapitalDealroom has a profile for this one. Try Dealroom →, and Shanzheng Investment also participated. The amount was not disclosed.

What does it do? Founded in 2022, the company develops, manufactures, and sells superconducting and cryogenic equipment. It serves five areas: nuclear fusion, scientific high-field magnets, photovoltaic semiconductors, superconducting magnetic separation, and high-end medical devices.

Why now? A month before the round closed, a consortium of Xihe and the Chinese Academy of Sciences' Hefei Institutes of Physical Science was named the first-choice bidder for the BEST fusion device's central solenoid magnet project, with a bid of US$68.7M. If it wins and delivers, the contract would bring engineering validation and a major order.

By the numbers: Combined with an early-year Series B, Xihe's two rounds this year total close to US$137.5M. The money will fund pre-research on core fusion components and production line construction.

What's the endgame? Xihe sits in the middle of the supply chain, turning purchased superconducting conductors into finished magnet systems rather than making the raw materials. Fusion is the highest-ceiling line, but scientific magnets, photovoltaic semiconductors, and medical devices generate current revenue and sharpen manufacturing consistency.

What could go wrong? Commercial fusion power remains distant, and funding activity does not equal technical or business success. Order timing depends on engineering progress, with long acceptance cycles and slow payment; the technology path has not settled.

The signal: Investors are backing the supply chain that fusion construction needs, not just reactor developers. With Chinese fusion companies and component suppliers raising actively, the real test is whether Xihe can turn research-project capability into repeatable manufacturing and steady income.

Read more: itjuzi.com

Image credit: Generated with Gemini

More top stories